We used clinical phosphoproteome data from the CPTAC database to compare ALK substrates in tumour tissues and NATs of EML4-ALK–positive NSCLC patients (Fig 7) and found that the phosphorylation of ALK and GMDS was increased in all tumour tissues, but the phosphorylation of SHC1 and PTPN11 was decreased in four patients and increased in three patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.